WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

DSM-Firmenich AG DSFIR

AmsterdamSpecialty chemicalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
Moat score
68
ROIC
2.2%
P/E
–
EV/EBIT
–
FCF yield
–
Dividend yield
–
Market cap
–

Moat ranks

Score rankTied #264 of 396
Durabilitymedium
Market structureOligopoly
Pricing powermoderate

Balance sheet

6/30/26
€BDec 31Jun 30
Cash1.82.3
Securities0.10.0
Debt4.86.8
Net cash-2.9-4.5
Equity18.217.8
Leverage
Debt / EBITDA
4.21×
Debt / equity
0.38×
Leases (12/31/25)
€463M
Capital
Diluted shares
–
Book value / share
–
Price / book
–
Net cash / share
–
Market cap
–
Enterprise value
–

Per-share record

Fiscal years and TTM
Scale
€0€20€40€60'23'2434.83'25TTM
Revenue per shareCash flow per share

Key indicators

Latest: H1 '26
IndicatorLatestVs year agoLast 8 halves
Revenue growth0.5%––
Operating margin7.9%-0.3 pts
FCF margin0.8%+3.1 pts
Capex / revenue9.9%+1.3 pts
Perfumery & Beauty sales (H1)€1.9B+2%
Perfumery & Beauty adjusted EBITDA (H1)€424M-0%
Perfumery & Beauty organic sales (H1) growth+7%––
Taste, Texture & Health sales (H1)€1.6B+0%
Taste, Texture & Health adjusted EBITDA (H1)€321M-4%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About DSFIR

DSM-Firmenich supplies scents, flavours and nutrition ingredients to consumer product makers. Perfumery & Beauty and Taste, Texture & Health benefit from proprietary ingredients, customer-specific application work and a broad formulation portfolio.

Revenue mix
Perfumery & Beauty 30.1%Animal Nutrition & Health 27.9%Taste, Texture & Health 25.2%Health, Nutrition & Care 16.8%
  • Supply Chain Control

    Own production of captive fragrance ingredients helps perfumers create distinctive formulas and secure supply.

  • Design In Qualification

    Customer briefs draw on the supplier's formulation and application expertise.

  • Design In Qualification

    Flavours and textures must work in a customer's specific recipe and production process.

  • Scope Economies

    Combining taste, texture and nutritional ingredients lets the company sell more solutions into an existing customer relationship.

Timeline
  1. Nov 4, 2026

    dsm-firmenich raised its FY2026 like-for-like sales growth outlook to around 5% from 2–4% after continued volume growth.

  2. Oct 19, 2026

    Shareholders elected Richard Ridinger as chair at the extraordinary general meeting.

  3. Oct 1, 2026

    DSM-Firmenich completed its EUR 540 million buyback, purchasing 7,169,147 shares; EUR 500 million supports capital reduction and EUR 40 million covers employee share plans.

  4. Sep 29, 2026

    The UK CMA confirmed its fragrance investigation involving Firmenich remains open, with its next update due in December. No infringement finding has been made, but regulatory uncertainty remains after the US settlement.

  5. Sep 16, 2026

    DSM-Firmenich expanded Karawang production and opened a shared Jakarta office, bringing its three continuing businesses closer to Indonesian customers.

Financial record

Fiscal year202320242025TTMTrendChange 2023–25
Per share (€)
Revenue45.5334.2234.83–-12.5%/yr
Cash flow5.426.725.57–+1.4%/yr
Earnings-2.821.321.31––
Free cash flow2.463.832.63–+3.4%/yr
Capex2.962.892.95–-0.3%/yr
Dividends2.492.492.54–+0.9%/yr
Book value98.1585.0870.33–-15.3%/yr
Diluted shares (M)233265259–+5.4%/yr
Totals (€B)
Revenue10.69.19.09.1-7.8%/yr
Operating income-0.50.50.70.7–
Net income-0.70.30.30.4–
Free cash flow0.61.00.70.8+9.0%/yr
Buybacks0.00.71.21.1–
Dividends0.60.70.70.6+6.4%/yr
Net cash-1.9-2.0-2.9-4.5−€1.1B
Margins & returns (%)
Gross margin24.639.239.139.2+14.5 pts
Operating margin-4.76.07.97.7+12.5 pts
Net margin-6.23.83.84.2+10.0 pts
FCF margin5.411.27.59.1+2.1 pts
ROIC-1.41.62.32.2+3.7 pts
Return on equity-2.91.51.92.1+4.7 pts
R&D % of revenue6.19.07.9–+1.8 pts
Stock pay % of revenue0.30.30.4–+0.1 pts
Capex % of revenue6.58.48.59.1+1.9 pts

Change uses 2023 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2023 base. Trend shows the fiscal years.

TTM = two half years to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 30.3% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score68
Strength
Confidence
Structure
Oligopoly
Durability
medium
Trajectory
stable
Pricing power
moderate
Segments
  • Perfumery & Beauty30.1%
    2 claims
  • Taste, Texture & Health25.2%
    2 claims
  • Health, Nutrition & Care16.8%
    1 claim
  • Animal Nutrition & Health27.9%
    1 claim

Moat claims

Applies to
Perfumery & Beauty
Confidence
Durability
medium
Trajectory
stableas of Jun 30, 2026
Why it holds

Own production of captive fragrance ingredients helps perfumers create distinctive formulas and secure supply. This protection covers proprietary molecules, not every aroma chemical; Aroma Ingredients has moved to the ANH disposal group.

Why stable

Perfumery & Beauty delivered 7% like-for-like sales growth and 6% like-for-like adjusted EBITDA growth in H1 2026, while proprietary captive molecules continue to support differentiated creations.

Indicators
  • Perfumery & Beauty sales (annual)€3.8B-0%
  • Perfumery & Beauty adjusted EBITDA (annual)€815M-3%
  • Perfumery & Beauty organic sales (annual) growth+3%
  • Perfumery & Beauty sales (H1)€1.9B+2%
  • Perfumery & Beauty adjusted EBITDA (H1)€424M-0%
  • Perfumery & Beauty organic sales (H1) growth+7%
  • Perfumery & Beauty price contribution (H1)0.0%
Risks
  • Regulatory restrictions on certain fragrance ingredients
  • Supply shocks in naturals and key chemical precursors
  • Large peers expand vertical integration or secure exclusive feedstocks

Profile change log

  1. Nov 10, 2026 · business change

    dsm-firmenich raised its FY2026 like-for-like sales growth outlook to around 5% from 2–4% after continued volume growth.

  2. Nov 10, 2026 · business change

    Shareholders elected Richard Ridinger as chair at the extraordinary general meeting.

  3. Oct 6, 2026 · analyst revision

    The ANH disposal debate now includes the estimated EUR 600 million of net cash proceeds, retained 20% equity stakes and potential financing support. The EUR 2.2 billion headline enterprise value is not the cash DSM-Firmenich expects to receive.

  4. Oct 6, 2026 · analyst revision

    The investment debate now separates the open competition case from restructuring execution and uses the July results release to support the HNC growth argument. Moat strengths and segment weights are unchanged.

  5. Oct 6, 2026 · business change

    The UK CMA confirmed its fragrance investigation involving Firmenich remains open, with its next update due in December. No infringement finding has been made, but regulatory uncertainty remains after the US settlement.

  6. Oct 6, 2026 · business change

    A US court preliminarily approved Firmenich's USD 33 million settlement with direct purchasers in fragrance antitrust litigation. Final approval is pending; Firmenich denies wrongdoing and other legal proceedings continue.

  7. Oct 6, 2026 · analyst revision

    The Perfumery & Beauty and Taste, Texture & Health customer-formulation moats are classified as design and qualification costs. The evidence concerns recipe testing and supplier approval, rather than employee training; claim strengths are unchanged.

  8. Oct 6, 2026 · business change

    DSM-Firmenich completed its EUR 540 million buyback, purchasing 7,169,147 shares; EUR 500 million supports capital reduction and EUR 40 million covers employee share plans.

  9. Oct 6, 2026 · business change

    DSM-Firmenich expanded Karawang production and opened a shared Jakarta office, bringing its three continuing businesses closer to Indonesian customers.

  10. Oct 6, 2026 · business change

    DSM-Firmenich partnered with Boltz to develop exclusive AI models for scent and flavour discovery, adding a route to faster molecule development; commercial gains remain unproven.

  11. Oct 6, 2026 · business change

    DSM-Firmenich sued Chinese entities over biotechnology production of Sclareol, seeking an injunction and damages to protect an ingredient production route; no ruling has been announced.

  12. Oct 6, 2026 · business change

    DSM-Firmenich proposed Richard Ridinger as chairman after Thomas Leysen announced retirement; shareholders vote on October 19.

  13. Oct 6, 2026 · business change

    DSM-Firmenich began trading on SIX alongside Amsterdam, broadening access to Swiss investors.

  14. Oct 6, 2026 · business change

    DSM-Firmenich agreed to sell ANH to CVC for an enterprise value of about EUR 2.2 billion, including an earnout of up to EUR 500 million; retained 20% stakes preserve some exposure.

  15. Oct 6, 2026 · business change

    DSM-Firmenich sold its Feed Enzymes Alliance stake to Novonesis for EUR 1.5 billion, removing the enzyme business and releasing cash.

  16. Oct 6, 2026 · business change

    DSM and Firmenich completed their merger, combining nutrition ingredients with fragrance and flavour creation; Firmenich enters reported results only from the merger date.

  17. Oct 6, 2026 · analyst revision

    Segment weights now use FY2025 restated sales; the six moat claims have sourced trajectories, linked market profiles and operating tests. The supply advantage is limited to proprietary ingredients after Aroma Ingredients moved to ANH.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianDSFIR
No peer numbers yet

Peers appear on the map as their numbers are collected.

Global B2B fragrance and beauty ingredients

As of Oct 6, 2026
OligopolyMedium cyclicality

Fragrance compounds, proprietary scent molecules and active beauty ingredients sold to perfume, personal care and home care manufacturers. This is an ingredient and formulation market; retail perfume and cosmetics sales are excluded.

  1. Givaudan
  2. DSM-Firmenich
  3. IFF
  4. Symrise
2025 leaders, no comparable shares · Givaudan
StocksMoatGross m.Op. m.
DSFIR6839.2%7.7%
Industry median117543.7%14.8%
Sector median147641.3%16.5%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Fine fragrance launches and growing interest in scent increase demand for new customer-specific creations.
  • Personal care and home care consumption provides repeat volume alongside the more discretionary fine fragrance business.
  • Online commerce and regional fragrance brands create new customer briefs and shorten product launch cycles.
  • Natural and biotechnology ingredients create reformulation opportunities and can reduce dependence on scarce natural inputs.
Risks
  • Consumer caution and customer destocking can reduce ingredient orders even when end-user consumption remains stable.
  • Energy, feedstock and natural ingredient costs can rise before contract prices reset; tariffs add sourcing and logistics costs.
  • A stronger reporting currency reduces translated sales and profit from global demand; company H1 2026 results show a material FX effect.
  • Ingredient restrictions require reformulation, while competition investigations and civil litigation create legal and customer-trust risks.
  • Higher interest rates raise the cost of carrying inventories and financing acquisitions for indebted suppliers; weaker consumer demand can extend the time between ingredient purchases and customer payment.

Bulls & bears

Key question · as of Oct 6, 2026

Can the three continuing businesses turn customer wins and merger synergies into stronger cash generation after ANH leaves, despite currency pressure and consumer caution?

Arguments

4 forFaded: weakening or settled6 against

What to watch

  1. 1Like-for-like sales and price versus volume by continuing business
  2. 2Taste, Texture & Health revenue synergies and adjusted EBITDA
  3. 3Continuing operating cash flow and ANH disposal completion

Next check: December 8, 2026 US settlement fairness hearing and December CMA update; ANH closing expected by end-2026; February 18, 2027 results for continuing operations and cash conversion.

Sources: company filings and dated sources collected for Find My Moat; A current closing price and matching share count have not been verified; market cap and valuation multiples are unavailable. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 68/100 by <a href="https://www.findmymoat.com/stocks/XAMS:DSFIR">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.